Royal Bank of Canada upgraded Outset Medical to 'outperform' with a $6.00 target price.

Royal Bank of Canada upgraded Outset Medical (OM) from sector perform to outperform with a $6.00 target price, up from $5.00. Analysts have a consensus "Moderate Buy" rating and a $5.42 target price. Outset Medical is a medical tech company focusing on hemodialysis in the US. Insiders and large investors, including Mubadala Investment Co PJSC, have increased their positions in the company.